Cue Biopharma Taps Kyverna Alumnus as CMO Amid Key Clinical Milestones
Event summary
- Dominic Borie, M.D., Ph.D., joins Cue Biopharma as Chief Medical Officer and Head of R&D effective July 13, 2026.
- Phase 2 CSU data readout for CUE-221 program expected by Q3 2026 end.
- Phase 1 trial initiation for CUE-401 planned by Q4 2026 end.
- $50M private placement completed to fund clinical development.
The big picture
Cue Biopharma's appointment of Dominic Borie comes as the company accelerates its immunology pipeline, with two key clinical readouts on the horizon. The move reflects a strategic push to strengthen leadership depth in advance of potential pivotal data that could validate its platform technology. In an increasingly competitive autoimmune space, Cue's ability to differentiate its bifunctional molecule approach will be critical for investor confidence.
What we're watching
- Pipeline Execution
- Whether Cue can deliver on its aggressive clinical timelines for both CUE-221 and CUE-401 programs.
- Leadership Impact
- How Dominic Borie's industry experience will shape Cue's immunology portfolio strategy.
- Financial Runway
- The pace at which the $50M private placement will be deployed and its sufficiency for near-term milestones.